JP2024539445A5 - - Google Patents

Info

Publication number
JP2024539445A5
JP2024539445A5 JP2024529482A JP2024529482A JP2024539445A5 JP 2024539445 A5 JP2024539445 A5 JP 2024539445A5 JP 2024529482 A JP2024529482 A JP 2024529482A JP 2024529482 A JP2024529482 A JP 2024529482A JP 2024539445 A5 JP2024539445 A5 JP 2024539445A5
Authority
JP
Japan
Prior art keywords
complexing agents
corticosteroid
colloidal suspension
active pharmaceutical
pharmaceutical ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539445A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080164 external-priority patent/WO2023092087A1/en
Publication of JP2024539445A publication Critical patent/JP2024539445A/ja
Publication of JP2024539445A5 publication Critical patent/JP2024539445A5/ja
Pending legal-status Critical Current

Links

JP2024529482A 2021-11-18 2022-11-18 硝子体内コルチコステロイド徐放性インプラント及び使用方法 Pending JP2024539445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163281052P 2021-11-18 2021-11-18
US63/281,052 2021-11-18
PCT/US2022/080164 WO2023092087A1 (en) 2021-11-18 2022-11-18 Intravitreal corticosteroid extended release implant and methods of use

Publications (2)

Publication Number Publication Date
JP2024539445A JP2024539445A (ja) 2024-10-28
JP2024539445A5 true JP2024539445A5 (OSRAM) 2025-11-20

Family

ID=86397883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529482A Pending JP2024539445A (ja) 2021-11-18 2022-11-18 硝子体内コルチコステロイド徐放性インプラント及び使用方法

Country Status (9)

Country Link
US (2) US12433900B2 (OSRAM)
EP (1) EP4433092A4 (OSRAM)
JP (1) JP2024539445A (OSRAM)
KR (1) KR20240124924A (OSRAM)
CN (1) CN117881411A (OSRAM)
AU (1) AU2022391750A1 (OSRAM)
CA (1) CA3238162A1 (OSRAM)
MX (1) MX2024006028A (OSRAM)
WO (1) WO2023092087A1 (OSRAM)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951014A (en) 1957-01-03 1960-08-30 Upjohn Co Process for a stable oil suspension
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
WO2004004682A2 (en) 2002-07-02 2004-01-15 Laboratorios S.A.L.V.A.T., S.A. Stable oily suspension of microgranules
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
US20050181050A1 (en) 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
CA2947330C (en) 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2012202035B2 (en) 2005-09-16 2014-03-20 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20100008982A1 (en) 2006-04-24 2010-01-14 Eyal Shimoni Non-covalent complexes of bioactive agents with starch for oral delivery
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
CA2713150C (en) 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
US20110105417A1 (en) 2008-06-26 2011-05-05 The Curators Of The University Of Missouri Drug Conjugates
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
DK2464371T3 (en) 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
EP2764871A1 (en) 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
WO2011091357A1 (en) 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
EP3511012A1 (en) 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
AU2013222237B2 (en) 2012-02-23 2017-10-05 Cornell University Aromatic-cationic peptides and uses of same
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
JP6480921B2 (ja) 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
WO2015048647A1 (en) 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
WO2015089316A1 (en) 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
WO2015095077A1 (en) 2013-12-16 2015-06-25 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
PL3160985T3 (pl) 2014-06-30 2021-12-27 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylo-l-fenyloalaninoamidu
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016057809A1 (en) 2014-10-10 2016-04-14 Therakine Mg stearate - based composite nanoparticles, methods of preparation and applications
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
US20170224764A1 (en) 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
CN109906075A (zh) 2016-04-29 2019-06-18 恩瑟拉德斯医药有限公司 用于在发炎病灶或区域中局部注射的脂质体皮质类固醇
EP3257863A1 (en) 2016-06-16 2017-12-20 Université de Strasbourg Flourous metabolically stable peptide analogs
WO2018034901A1 (en) 2016-08-16 2018-02-22 Stealth Biotherapeutics N-carboxyanhydride-based-scale synthesis of elamipretide
HUE057221T2 (hu) * 2016-11-29 2022-04-28 Oculis SA Szilárd ciklodextrin komplexek készítményei szemészetileg aktív gyógyászati hatóanyag adagolásához
EP3720455A4 (en) 2017-12-08 2021-09-22 The University of Washington METHODS AND COMPOSITIONS FOR DETECTING AND PROMOTING CARDIOLIPID REMODELING AND CARDIOMYOCYTE MATURATION AND RELATED METHODS FOR TREATING MITOCHONDRIAL DYSFUNCTION
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
ES2941266T3 (es) 2018-04-02 2023-05-19 Stealth Biotherapeutics Inc Dipéptidos cristalinos útiles en la síntesis elamipretide
JP2021531328A (ja) 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ−α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン−アスパラギン酸プロテアーゼを含む薬剤送達系
WO2020006125A1 (en) 2018-06-26 2020-01-02 Ribonova Inc. Methods of treating mitochondrial dysfunction
WO2020255138A1 (en) 2019-06-20 2020-12-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Composites and uses thereof

Similar Documents

Publication Publication Date Title
JP6683787B2 (ja) 眼房内ビマトプロスト注入物による眼圧低下
RU2664686C2 (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
Lee et al. Biodegradable implants for sustained drug release in the eye
CN104994815B (zh) 持续药物递送植入物
Mansoor et al. Intraocular sustained-release delivery systems for triamcinolone acetonide
US20130071349A1 (en) Biodegradable polymers for lowering intraocular pressure
JP2009167197A (ja) 結膜下デポによるドラッグデリバリーシステム
EP4210682A1 (en) Bioerodible ocular drug delivery insert and therapeutic method
JP2021502366A (ja) 効果の持続期間が延長された眼内圧降下用徐放性インプラント
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
WO2005018608A1 (ja) 微粒子テノン嚢下投与ドラッグデリバリーシステム
JP2022535223A (ja) 眼疾患治療用組成物
US20250222007A1 (en) Preparation of low molecular weight polylactic acid and the use thereof
민창희 IONTOPHORETIC DELIVERY OF DRUG-LOADED PLGA NANOPARTICLES TO THE PREOCULAR SURFACE FOR ENHANCED DRUG BIOAVAILABILITY
Bossy et al. Intraocular implants for controlled drug delivery
Chauhan et al. ISSN 2320-138X
HK1244665B (en) Intraocular pressure reduction with intracameral prostamide implants
HK1165708A (en) Intracameral sustained release drug delivery systems
HK1165708B (en) Intracameral sustained release drug delivery systems